Abstract

The direct oncolytic effect of Newcastle disease virus (NDV) depends on the following two aspects: the susceptibility of cancer cells to virus infection and the ability of virus itself to lyse cancer cells. First, we investigate the susceptibility of cancer cells to NDV infection, HepG2, MDA-MB-231, and SH-SY5Y cells were susceptible, A549, MCF7, and LoVo cells were less susceptible. To investigate the molecular mechanism responsible for cancer cell susceptibility, transcriptome sequencing was carried out. We found that the levels of alpha-sialic acid acyltransferase were upregulated in MDA-MB-231 cells compared with MCF7 cells, and the interferon was downregulated. Second, to optimize the oncolytic capacity of the wild-type rClone30, a series of chimeric viruses rClone30-Anh(HN), rClone30-Anh(F), and rClone30-Anh(HN-F) were constructed by exchanging the HN gene, F gene or both of non-lytic rClone30 strain with lytic strain Anhinga. rClone30-Anh(F) and rClone30-Anh(HN-F) enhanced the oncolytic effect of the rClone30, and this enhancement is more obvious in the susceptible cells. The oncolytic mechanism of rClone30-Anh(F) was analyzed by transcriptome analyses, in comparison with rClone30, rClone30-Anh(F) upregulated the expression of ATG5, Beclin 1, and MAP1LC3B, thus activating autophagy and promoting the production of syncytia. In conclusion, our study provides a strategy to enhance the oncolytic effect of rClone30.

Highlights

  • Newcastle disease virus (NDV) is an avian paramyxovirus with a negative single-strand RNA genome and it has been shown to be a potent oncolytic agent with an attractive safety profile in humans in phase I and II clinical trials [1, 2]

  • There was no significant difference between rClone30 and chimeric virus rClone30-Anh(HN) in growth. These results indicate that the replacement of HN gene dose not influence the growth kinetics of rClone30 and the replacement of F gene enhance the fusogenic property of rClone30

  • NDV as one of the oncolytic viruses represents a new class of therapeutic agents of cancer therapy

Read more

Summary

Introduction

Newcastle disease virus (NDV) is an avian paramyxovirus with a negative single-strand RNA genome and it has been shown to be a potent oncolytic agent with an attractive safety profile in humans in phase I and II clinical trials [1, 2]. NDV exhibits several advantages when compared with other oncolytic agents in development [3]. NDV is an avian pathogen, more than half century application of the virus as an avian vaccine demonstrates a super genome stability [4]. Serological studies indicated that ~96% of the human population is seronegative for NDV, avoiding the problem of preexisting immunity in humans, which is potential problems with vaccinia virus, herpes simplex virus, and adenovirus [5]. Despite the advantages discussed above, results from clinical trials are not satisfactory [7,8,9]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call